VX-147 in Subjects Aged 12 Years and Older with APOL1-mediated Kidney Disease

Nephrology
Ekamol Tantisattamo
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Adult and Pediatric Subjects With APOL1-mediated Proteinuric Kidney Disease
Kidney - Nephrology

Study Description

Eligibility

  1. APOL1 genotype of G1/G1, G2/G2, or G1/G2
  2. Proteinuric kidney disease

Key

  1. Solid organ or bone marrow transplant
  2. Uncontrolled hypertension
  3. History of diabetes mellitus
  4. Known underlying cause of kidney disease including but not limited to sickle cell disease

Other protocol defined Inclusion/Exclusion criteria apply.

A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.